Details of the Drug

General Information of Drug (ID: DMRKXPT)

Drug Name

Ketoprofen

Synonyms

Actron; Alrheumat; Alrheumum; Alrheumun; Aneol; Capisten; Dexal; Epatec; Fastum; Kefenid; Ketoprofene; Ketoprofeno; Ketoprofenum; Ketopron; Ketoprophene; Lertus; Menamin; Meprofen; Orudis; Orugesic; Oruvail; Oscorel; Profenid; Toprec; Toprek; Benzoylhydratropic Acid; Orudis KT; K 1751; RP 19583; RP19583; RU 4733; Arthril (TN); Fastum (TN); Fastum Gel (TN); Iso-K; Keto (TN); Ketoflam (TN); Ketomex (TN); Ketonal (TN); Ketoprofenas (TN); Ketoprofene (TN); Ketoprofene [INN-French]; Ketoprofeno [INN-Spanish]; Ketoprofenum (TN); Ketoprofenum [INN-Latin]; Ketorin (TN); Ketospray (TN); Lasonil (TN); M-Benzoylhydratropic acid; Oki (TN); Orudis (TN); Oruvail (TN); RP-19583; Racemic-Ketoprofen; Zon (TN); Bi-Profnid (TN); RP, 19,583; Ketoprofen (JP15/USP/INN); Ketoprofen [USAN:INN:BAN:JAN]; Orudis, Oruvail, Ketoflam, Orudis KT, Ketoprofen; Acide (benzoyl-3-phenyl)-2-propionique; Acide (benzoyl-3-phenyl)-2-propionique [French]; L'Acide (benzoyl-3-phenyl)-2-propionique; (+-)-m-Benzoylhydratropic acid; 2-(3-Benzoylphenyl)propanoic acid; 2-(3-Benzoylphenyl)propionic acid; 2-(m-Benzoylphenyl)propionic acid; 2-[3-(benzoyl)phenyl]propanoic acid; 2-[3-(phenylcarbonyl)phenyl]propanoic acid; 2-[3-Benzoylphenyl]propionic acid; 3-Benzoylhydratropic acid

Indication

Disease Entry	ICD 11	Status	REF
Musculoskeletal pain	MG30	Approved	[1], [2]
Pain	MG30-MG3Z	Phase 3	[3], [4]
Migraine	8A80	Phase 2	[5]
Osteoarthritis	FA00-FA05	Phase 1	[5]

Therapeutic Class

Analgesics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

254.28

Topological Polar Surface Area (xlogp)

3.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption: The drug is rapidly and well-absorbed orally [6]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 0.5-2 h [6]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [7]
Bioavailability: 90% of drug becomes completely available to its intended biological destination(s) [8]
Clearance: The drug present in the plasma can be removed from the body at the rate of 1.6 mL/min/kg [9]
Elimination: 0.5% of drug is excreted from urine in the unchanged form [7]
Half-life: The concentration or amount of drug in body reduced by one-half in 1.1 - 4 hours [9]
Metabolism: The drug is metabolized via the liver [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 19.66259 micromolar/kg/day [10]
Unbound Fraction: The unbound fraction of drug in plasma is 0.008% [9]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.13 L/kg [9]
Water Solubility: The ability of drug to dissolve in water is measured as 0.18 mg/mL [7]

Chemical Identifiers

Formula: C16H14O3
IUPAC Name: 2-(3-benzoylphenyl)propanoic acid
Canonical SMILES: CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O
InChI: InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)
InChIKey: DKYWVDODHFEZIM-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3825
ChEBI ID: CHEBI:6128
CAS Number: 22071-15-4
DrugBank ID: DB01009
TTD ID: D0W9WF
VARIDT ID: DR00690
INTEDE ID: DR0907
ACDINA ID: D00343

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin G/H synthase 2 (COX-2)	TTVKILB	PGH2_HUMAN	Inhibitor	[11]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[12]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Musculoskeletal pain

ICD Disease Classification

MG30

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Prostaglandin G/H synthase 2 (COX-2)	DTT	PTGS2	1.64E-44	1.57	1.7
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DME	UGT1A1	3.70E-05	-8.48E-02	-3.30E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	1.35E-09	-5.03E-01	-6.35E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Ketoprofen

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Levomilnacipran	DMV26S8	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Levomilnacipran.	Chronic pain [MG30]	[42]
-----------

Coadministration of a Drug Treating the Disease Different from Ketoprofen (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Ketoprofen and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[43]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Ketoprofen and Glibenclamide.	Acute diabete complication [5A2Y]	[44]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Ketoprofen and Glipizide.	Acute diabete complication [5A2Y]	[44]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Ketoprofen caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[45]
Inotersen	DMJ93CT	Major	Increased risk of nephrotoxicity by the combination of Ketoprofen and Inotersen.	Amyloidosis [5D00]	[45]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Ketoprofen and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[46]
Cilostazol	DMZMSCT	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Cilostazol.	Arterial occlusive disease [BD40]	[47]
Budesonide	DMJIBAW	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Ketoprofen and Budesonide.	Asthma [CA23]	[48]
Ofloxacin	DM0VQN3	Moderate	Additive CNS depression effects by the combination of Ketoprofen and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[49]
Kanamycin	DM2DMPO	Moderate	Increased risk of nephrotoxicity by the combination of Ketoprofen and Kanamycin.	Bacterial infection [1A00-1C4Z]	[50]
Sparfloxacin	DMB4HCT	Moderate	Additive CNS depression effects by the combination of Ketoprofen and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[49]
Streptomycin	DME1LQN	Moderate	Increased risk of nephrotoxicity by the combination of Ketoprofen and Streptomycin.	Bacterial infection [1A00-1C4Z]	[50]
Gemifloxacin	DMHT34O	Moderate	Additive CNS depression effects by the combination of Ketoprofen and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[49]
Norfloxacin	DMIZ6W2	Moderate	Additive CNS depression effects by the combination of Ketoprofen and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[49]
ABT-492	DMJFD2I	Moderate	Additive CNS depression effects by the combination of Ketoprofen and ABT-492.	Bacterial infection [1A00-1C4Z]	[49]
Levofloxacin	DMS60RB	Moderate	Additive CNS depression effects by the combination of Ketoprofen and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[49]
Etidronic acid	DM1XHYJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Ketoprofen and Etidronic acid.	Bone paget disease [FB85]	[51]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Ketoprofen and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[52]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Ketoprofen caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[53]
Trastuzumab Emtansine	DMU1LXS	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Trastuzumab Emtansine.	Breast cancer [2C60-2C6Y]	[47]
Iodipamide	DMXIQYS	Major	Increased risk of nephrotoxicity by the combination of Ketoprofen and Iodipamide.	Cholelithiasis [DC11]	[54]
Regorafenib	DMHSY1I	Major	Increased risk of bleeding by the combination of Ketoprofen and Regorafenib.	Colorectal cancer [2B91]	[45]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Ketoprofen and Drospirenone.	Contraceptive management [QA21]	[55]
Methoxyflurane	DML0RAE	Moderate	Increased risk of nephrotoxicity by the combination of Ketoprofen and Methoxyflurane.	Corneal disease [9A76-9A78]	[45]
Ardeparin	DMYRX8B	Major	Increased risk of bleeding by the combination of Ketoprofen and Ardeparin.	Coronary thrombosis [BA43]	[56]
Danaparoid	DM6CLBN	Major	Increased risk of bleeding by the combination of Ketoprofen and Danaparoid.	Deep vein thrombosis [BD71]	[56]
Rivaroxaban	DMQMBZ1	Major	Increased risk of bleeding by the combination of Ketoprofen and Rivaroxaban.	Deep vein thrombosis [BD71]	[57]
Sertraline	DM0FB1J	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Sertraline.	Depression [6A70-6A7Z]	[42]
Vilazodone	DM4LECQ	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Vilazodone.	Depression [6A70-6A7Z]	[42]
Vortioxetine	DM6F1PU	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Vortioxetine.	Depression [6A70-6A7Z]	[42]
Milnacipran	DMBFE74	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Milnacipran.	Depression [6A70-6A7Z]	[42]
Escitalopram	DMFK9HG	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Escitalopram.	Depression [6A70-6A7Z]	[42]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Desvenlafaxine.	Depression [6A70-6A7Z]	[42]
Clomipramine	DMINRKW	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Clomipramine.	Depression [6A70-6A7Z]	[42]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Ketoprofen and Cannabidiol.	Epileptic encephalopathy [8A62]	[45]
Tazemetostat	DMWP1BH	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Tazemetostat.	Follicular lymphoma [2A80]	[47]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Ketoprofen and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[45]
Sulfinpyrazone	DMEV954	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Sulfinpyrazone.	Gout [FA25]	[47]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Ketoprofen and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[58]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Ketoprofen and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[59]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Ketoprofen and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[60]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Ketoprofen and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[61]
Trichlormethiazide	DMHAQCO	Moderate	Antagonize the effect of Ketoprofen when combined with Trichlormethiazide.	Hypertension [BA00-BA04]	[62]
Balsalazide	DMO091F	Moderate	Increased risk of nephrotoxicity by the combination of Ketoprofen and Balsalazide.	Indeterminate colitis [DD72]	[63]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Ketoprofen caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[43]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[64]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Ketoprofen and Idelalisib.	Mature B-cell leukaemia [2A82]	[65]
Acalabrutinib	DM7GCVW	Major	Increased risk of bleeding by the combination of Ketoprofen and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[66]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Ketoprofen and Ibrutinib.	Mature B-cell lymphoma [2A85]	[67]
Ponatinib	DMYGJQO	Major	Increased risk of bleeding by the combination of Ketoprofen and Ponatinib.	Mature B-cell lymphoma [2A85]	[68]
Exjade	DMHPRWG	Major	Increased risk of nephrotoxicity by the combination of Ketoprofen and Exjade.	Mineral absorption/transport disorder [5C64]	[69]
Deflazacort	DMV0RNS	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Ketoprofen and Deflazacort.	Muscular dystrophy [8C70]	[48]
Dasatinib	DMJV2EK	Major	Increased risk of bleeding by the combination of Ketoprofen and Dasatinib.	Myeloproliferative neoplasm [2A20]	[70]
Omacetaxine mepesuccinate	DMPU2WX	Major	Increased risk of bleeding by the combination of Ketoprofen and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[71]
Prasugrel	DM7MT6E	Major	Increased risk of bleeding by the combination of Ketoprofen and Prasugrel.	Myocardial infarction [BA41-BA43]	[45]
Vorapaxar	DMA16BR	Major	Increased risk of bleeding by the combination of Ketoprofen and Vorapaxar.	Myocardial infarction [BA41-BA43]	[72]
Sibutramine	DMFJTDI	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Sibutramine.	Obesity [5B80-5B81]	[42]
Dexfenfluramine	DMJ7YDS	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Dexfenfluramine.	Obesity [5B80-5B81]	[42]
Polythiazide	DMCH80F	Moderate	Antagonize the effect of Ketoprofen when combined with Polythiazide.	Oedema [MG29]	[62]
MK-4827	DMLYGH4	Moderate	Increased risk of bleeding by the combination of Ketoprofen and MK-4827.	Ovarian cancer [2C73]	[45]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Epoprostenol.	Pulmonary hypertension [BB01]	[73]
Iloprost	DMVPZBE	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Iloprost.	Pulmonary hypertension [BB01]	[73]
Everolimus	DM8X2EH	Major	Increased risk of nephrotoxicity by the combination of Ketoprofen and Everolimus.	Renal cell carcinoma [2C90]	[74]
Temsirolimus	DMS104F	Major	Increased risk of nephrotoxicity by the combination of Ketoprofen and Temsirolimus.	Renal cell carcinoma [2C90]	[74]
Gatifloxacin	DMSL679	Moderate	Additive CNS depression effects by the combination of Ketoprofen and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[49]
Dexamethasone	DMMWZET	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Ketoprofen and Dexamethasone.	Rheumatoid arthritis [FA20]	[48]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Ketoprofen and Leflunomide.	Rheumatoid arthritis [FA20]	[60]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Ketoprofen and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[45]
Pitolisant	DM8RFNJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Ketoprofen and Pitolisant.	Somnolence [MG42]	[45]
Caplacizumab	DMPUKA7	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Caplacizumab.	Thrombocytopenia [3B64]	[47]
Apixaban	DM89JLN	Major	Increased risk of bleeding by the combination of Ketoprofen and Apixaban.	Thrombosis [DB61-GB90]	[45]
Cangrelor	DM8JRH0	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Cangrelor.	Thrombosis [DB61-GB90]	[47]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Brilinta.	Thrombosis [DB61-GB90]	[45]
Cabozantinib	DMIYDT4	Major	Increased risk of bleeding by the combination of Ketoprofen and Cabozantinib.	Thyroid cancer [2D10]	[75]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Ketoprofen and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[44]
Olsalazine	DMZW9HA	Moderate	Increased risk of nephrotoxicity by the combination of Ketoprofen and Olsalazine.	Ulcerative colitis [DD71]	[63]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Ketoprofen and Plazomicin.	Urinary tract infection [GC08]	[50]
Betrixaban	DM2C4RF	Major	Increased risk of bleeding by the combination of Ketoprofen and Betrixaban.	Venous thromboembolism [BD72]	[76]
-----------


⏷ Show the Full List of 78 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 28	E00491	6097185	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Dextrin	E00359	62698	Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Dibutyl sebacate	E00160	7986	Plasticizing agent
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
--------------------


⏷ Show the Full List of 21 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Ketoprofen 200 mg capsule	200 mg	24 HR Extended Release Oral Capsule	Oral
Ketoprofen 50 mg capsule	50 mg	Oral Capsule	Oral
Ketoprofen 75 mg capsule	75 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4795).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 073516.
3	Ketoprofen-induced cyclooxygenase inhibition in renal medulla and platelets of rats treated with caffeine. Pharmacology. 2001;63(4):234-9.
4	Synthesis and biological testing of Acyl-CoA-ketoprofen conjugates as selective irreversible inhibitors of COX-2. Bioorg Med Chem. 2002 Mar;10(3):753-7.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7	BDDCS applied to over 900 drugs
8	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
9	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
10	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
11	Probing the skin permeation of fish oil/EPA and ketoprofen-3. Effects on epidermal COX-2 and LOX. Prostaglandins Leukot Essent Fatty Acids. 2007 Jun;76(6):357-62.
12	Clinical pharmacokinetics of ketoprofen enantiomers in wild type of Cyp 2c8 and Cyp 2c9 patients with rheumatoid arthritis. Eur J Drug Metab Pharmacokinet. 2011 Sep;36(3):167-73.
13	Association between the UGT1A1*28 allele and hyperbilirubinemia in HIV-positive patients receiving atazanavir: a meta-analysis. Biosci Rep. 2019 May 2;39(5). pii: BSR20182105.
14	Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
15	Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
16	Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
17	UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
18	Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
19	Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
20	Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
21	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
22	Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
23	Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
24	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
25	Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
26	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
27	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
28	Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
29	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
30	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
31	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
32	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
33	Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
34	Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
35	Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
36	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
37	Pfizer. Product Development Pipeline. March 31 2009.
38	Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
39	Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
40	Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
41	Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
42	Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
43	Cerner Multum, Inc. "Australian Product Information.".
44	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
45	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
46	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
47	Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
48	Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
49	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
50	Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
51	Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
52	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
53	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
54	Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
55	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
56	Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
57	Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
58	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
59	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
60	EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
61	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
62	Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
63	Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
64	Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
65	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
66	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
67	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
68	Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
69	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
70	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
71	Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
72	Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
73	Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
74	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
75	Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
76	Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.